Success Metrics

Completion Rate

0%(0/2)

Active Trials

0(0%)

Terminated

2(100%)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 3Large-scale testing

2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials

Showing 2 of 2

terminatedphase_3

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

NCT05128773

terminatedphase_3

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

NCT04478266

Clinical Trials (2)

Showing 2 of 2 trials

NCT05128773Phase 3

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Terminated

NCT04478266Phase 3

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated

All 2 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 2